IOS Press is proud to announce its acquisition by Sage, bringing together two passionate, independent academic publishers. This collaboration will enrich the Sage portfolio, from AI to neuroscience, and build on IOS Press's 36-year legacy of excellence. Read more:

The Kidney Cancer Association is the proud media partner of the IKCS 2023. View the program and speakers at 👉 bit.ly/IKCSNA23 #Kidneycancer #IKCSNA23 Kidney Cancer

The Kidney Cancer Journal is the proud media partner of the IKCS 2023. View the program and speakers at 👉 bit.ly/IKCSNA23 #Kidneycancer #IKCSNA23 Kidney Cancer

Recently In Kidney Cancer 👉Remarkable review on adjuvant Rx in localized or locoregional #RCC 👉w/ sunitinib improving DFS, and recent data showing improved OS w/ pembro, Rx options in this setting are ⬆️👉tinyurl.com/4euc6yw2 OncoAlert UroToday.com #LukeWang Rana McKay, MD, FASCO

Recently in Kidney Cancer 👉Interesting real-world study on #Axitinib as 2L Rx or beyond of advanced/metastatic #RCC in the STAR-TOR registry 👉⬆️LDH could be a⛔️predictive marker for #Axitinib effectiveness👉tinyurl.com/mrx74xkn OncoAlert UroToday.com Annemarie Uhlig #ArneStrauß

Congrats Tom @tompowles 👉 for being named among top 10 influencers within the world of science by nature 👉Nature team selected 10 people who helped shape science in 2023👇Weblink of the article👉 tinyurl.com/3xdjxxad Uromigos OncoAlert ASCO ESMO - Eur. Oncology BBC News (UK) CNN CBS

Just In Kidney Cancer: Real-world study shows tumor-specific gene expression by RNA sequencing could serve as a potential biomarker of response to ipi + nivo Rx for mRCC #kidneycancer @tripNish Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO👉tinyurl.com/mr3xfutf OncoAlert KidneyCAN UroToday.com

Just in Kidney Cancer👉Excellent review on emerging ADCs in mRCC #KidneyCancer👉several potential targets were identified, and many promising candidates are currently under investigation👇👇tinyurl.com/mrydnwdp @HCGottlich Reza Nabavizadeh, MD Fabrice Lucien, PhD OncoAlert UroToday.com KidneyCAN

Just in 👉Full length #GU24 ASCO abstracts are now available online (except LBAs). Here is the weblink👉 tinyurl.com/3eearrj9 UroToday.com OncoAlert Uromigos PCF Science Bladder Cancer Advocacy Network KidneyCAN Kidney Cancer #ASCODailyNews

Just in Kidney Cancer 👉Excellent systematic review by Eric Jonasch on different Rx modalities for VHL-associated RCC #kidneycancer 👉Responses were observed w/ systemic Rx, including belzutifan, warranting additional studies👉tinyurl.com/5xh9w9bc OncoAlert UroToday.com KidneyCAN

Grateful for the opportunity to discuss advances in bladder, prostate, and kidney cancers with the incredible Rana McKay, MD, FASCO and Neeraj Agarwal, MD, FASCO what a time for urologic oncology! University of Utah Urology Huntsman Cancer Institute Society of Urologic Oncology YUO

Just in Kidney Cancer 👉Excellent review by drfrankiejs Tom Powles on adjuvant Rx in RCC #kidneycancer 👉w/ the +ve results of KEYNOTE-564, biomarkers are needed to identify pts who may benefit from adj Rx👇👇 tinyurl.com/y6w52prn Uromigos OncoAlert KidneyCAN Kidney Cancer

Just in Kidney Cancer 👉Insightful commentary by Shuchi Gulati MD @primolaraMD on recent LITESPARK-005 data from #ESMO23 in advanced ccRCC #kidneycancer👉belzutifan showed improved PFS & QoL outcomes over everolimus👇👇 tinyurl.com/37zyyee9 OncoAlert UroToday.com KidneyCAN

Delving into GU Oncology, we’re thrilled to spotlight the top voices in the field - as selected by peer survey. Thank you to these experts for their invaluable work in advancing cancer care. Your efforts truly make a difference. 🌟 #GUOncology #LARVOL #Oncology

Just in Kidney Cancer 👉Excellent review by #MartaAmannArévalo Javier Puente on different molecularly defined RCC #kidneycancer & their Rx 👉further research is needed to identify beneficial therapies in these subgroups 👇👇 tinyurl.com/bp632yzb UroToday.com OncoAlert KidneyCAN

Just in Kidney Cancer 👉Excellent review by #AlbertLee James Yu on the role of radiation therapy (SBRT) in the Rx of localized and oligometastatic RCC #kidneycancer👉SBRT use will likely increase in the future 👇👇 tinyurl.com/y3upcu8m UroToday.com OncoAlert KidneyCAN

Just in Kidney Cancer 👉Interesting study by #LunavandenBrink Patricia Zondervan comparing outcomes of radical vs. partial nephrectomy in pts w/ cT1b RCC #kidneycancer👉10-year survival rates were similar between both groups👇 tinyurl.com/bdzm9b5b UroToday.com OncoAlert KidneyCAN

Just in Kidney Cancer 👉Excellent review by Albert Jang, MD @ShilpaOnc on papillary RCC #kidneycancer👉Despite improved outcomes with VEGF-TKIs and ICIs, more dedicated clinical trials to pRCC are urgently needed👇 tinyurl.com/4cpsha2p UroToday.com OncoAlert KidneyCAN Kidney Cancer

Just in Kidney Cancer👉Interesting systematic review by #AlfredoDistante Stijn Muselaers on pt selection for active surveillance of small renal masses #kidneycancer👉Age, cardiovascular index & CKD were associated with⬇️OS👇 tinyurl.com/2ty3dna5 OncoAlert UroToday.com KidneyCAN

Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute